388 related articles for article (PubMed ID: 27913543)
41. Costs and utilization of hemophilia A and B patients with and without inhibitors.
Armstrong EP; Malone DC; Krishnan S; Wessler MJ
J Med Econ; 2014 Nov; 17(11):798-802. PubMed ID: 25111634
[TBL] [Abstract][Full Text] [Related]
42. Assessing the benefits of FEIBA prophylaxis in haemophilia patients with inhibitors.
Valentino LA
Haemophilia; 2010 Mar; 16(2):263-71. PubMed ID: 20028421
[TBL] [Abstract][Full Text] [Related]
43. Toward optimal therapy for inhibitors in hemophilia.
Kempton CL; Meeks SL
Blood; 2014 Nov; 124(23):3365-72. PubMed ID: 25428222
[TBL] [Abstract][Full Text] [Related]
44. New approaches in the management of inhibitor patients.
Young G
Acta Haematol; 2006; 115(3-4):172-9. PubMed ID: 16549892
[TBL] [Abstract][Full Text] [Related]
45. Cost and outcome: comparisons of two alternative bypassing agents for persons with haemophilia A complicated by an inhibitor.
Steen Carlsson K; Astermark J; Donfield S; Berntorp E
Thromb Haemost; 2008 Jun; 99(6):1060-7. PubMed ID: 18521509
[TBL] [Abstract][Full Text] [Related]
46. Recombinant clotting factors in the treatment of hemophilia.
Lee C
Thromb Haemost; 1999 Aug; 82(2):516-24. PubMed ID: 10605745
[No Abstract] [Full Text] [Related]
47. FEIBA versus NovoSeven in hemophilia patients with inhibitors.
Franchini M; Coppola A; Tagliaferri A; Lippi G
Semin Thromb Hemost; 2013 Oct; 39(7):772-8. PubMed ID: 24014071
[TBL] [Abstract][Full Text] [Related]
48. The value of early treatment in patients with haemophilia and inhibitors.
Kavakli K; Yesilipek A; Antmen B; Aksu S; Balkan C; Yilmaz D; Kupesiz A; Sasmaz I; Lindgren P; Mesterton J
Haemophilia; 2010 May; 16(3):487-94. PubMed ID: 20088956
[TBL] [Abstract][Full Text] [Related]
49. Hemophilia in Iran.
Dorgalaleh A; Dadashizadeh G; Bamedi T
Hematology; 2016 Jun; 21(5):300-10. PubMed ID: 26914731
[TBL] [Abstract][Full Text] [Related]
50. Views on methods for monitoring recombinant factor VIIa in inhibitor patients.
Key NS; Nelsestuen GL
Semin Hematol; 2004 Jan; 41(1 Suppl 1):51-4. PubMed ID: 14872422
[TBL] [Abstract][Full Text] [Related]
51. Emicizumab for the treatment of haemophilia A: a narrative review.
Franchini M; Marano G; Pati I; Candura F; Profili S; Veropalumbo E; Masiello F; Catalano L; Piccinini V; Vaglio S; Pupella S; Liumbruno GM
Blood Transfus; 2019 May; 17(3):223-228. PubMed ID: 31246563
[TBL] [Abstract][Full Text] [Related]
52. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. French FEIBA Study Group. Factor Eight Bypassing Activity.
Negrier C; Goudemand J; Sultan Y; Bertrand M; Rothschild C; Lauroua P
Thromb Haemost; 1997 Jun; 77(6):1113-9. PubMed ID: 9241742
[TBL] [Abstract][Full Text] [Related]
53. PRO-PACT: retrospective observational study on the prophylactic use of recombinant factor VIIa in hemophilia patients with inhibitors.
Young G; Auerswald G; Jimenez-Yuste V; Lambert T; Morfini M; Santagostino E; Blanchette V
Thromb Res; 2012 Dec; 130(6):864-70. PubMed ID: 22964026
[TBL] [Abstract][Full Text] [Related]
54. A Phase II clinical trial of a mixture of plasma-derived factor VIIa and factor X (MC710) in haemophilia patients with inhibitors: haemostatic efficacy, safety and pharmacokinetics/pharmacodynamics.
Shirahata A; Fukutake K; Takamatsu J; Shima M; Hanabusa H; Mugishima H; Amano K; Takedani H; Tamashima S; Matsushita T; Tawa A; Tanaka I; Higasa S; Kosaka Y; Fujii T; Sakai M; Migita M; Kawakami K; Ohashi Y; Saito H
Haemophilia; 2013 Nov; 19(6):853-60. PubMed ID: 23738888
[TBL] [Abstract][Full Text] [Related]
55. Eptacog beta: a novel recombinant human factor VIIa for the treatment of hemophilia A and B with inhibitors.
Biron-Andreani C; Schved JF
Expert Rev Hematol; 2019 Jan; 12(1):21-28. PubMed ID: 30577721
[TBL] [Abstract][Full Text] [Related]
56. Prophylaxis in haemophilia patients with inhibitors.
Leissinger CA
Haemophilia; 2006 Dec; 12 Suppl 6():67-72; discussion 72-3. PubMed ID: 17123397
[TBL] [Abstract][Full Text] [Related]
57. Feasibility of using thrombin generation assay (TGA) for monitoring bypassing agent therapy in patients with hemophilia having inhibitors.
Ay Y; Balkan C; Karapinar DY; Akin M; Bilenoglu B; Kavakli K
Clin Appl Thromb Hemost; 2013; 19(4):389-94. PubMed ID: 22395575
[TBL] [Abstract][Full Text] [Related]
58. Identifying non-responsive bleeding episodes in patients with haemophilia and inhibitors: a consensus definition.
Berntorp E; Collins P; D'Oiron R; Ewing N; Gringeri A; Négrier C; Young G
Haemophilia; 2011 Jan; 17(1):e202-10. PubMed ID: 20825500
[TBL] [Abstract][Full Text] [Related]
59. Single-dose recombinant activated factor VII therapy in hemophilia patients with inhibitors.
Kenet G; Martinowitz U
Semin Hematol; 2008 Apr; 45(2 Suppl 1):S38-41. PubMed ID: 18544424
[TBL] [Abstract][Full Text] [Related]
60. Inhibitors in hemophilia A: advances in elucidation of inhibitory mechanisms and in inhibitor management with bypassing agents.
Ananyeva NM; Lee TK; Jain N; Shima M; Saenko EL
Semin Thromb Hemost; 2009 Nov; 35(8):735-51. PubMed ID: 20169510
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
